Business Wire

MOTORK

Share
MotorK reports solid top-line performance in the third quarter with revenue up 86% year-over-year and adjusted EBITDA margin of 17.5%

MotorK, plc (AMS: MTRK) (“MotorK” or “the Group"), a leading SaaS provider for the automotive retail industry in the EMEA region, today reported financial results for the third quarter ended September 30, 2021.

Third Quarter 2021 and Other Recent Financial and Operating Highlights:

  • Revenue of €8.1 million in Q3 2021, up 86% compared to Q3 2020;
  • Revenue of €20.9 million for the first 9 months of 2021, up 54% compared to the same period in 2020;
  • Adjusted EBITDA was €1.4 million in Q3 2021, representing an adjusted EBITDA margin of 17.5%;
  • Adjusted EBITDA was €1.8 million for the first 9 months of 2021, representing an adjusted EBITDA margin of 8.6%;
  • Revenue and adjusted EBITDA growth driven by the strong performance of SaaS platform revenue in 2021 YTD, which was up 73% year-on-year;
  • Total R&D spend reached €2.0 million in Q3 2021, up 53% compared to €1.3 million R&D spend in Q3 2020, leading to a total of €5.4 million, or 26% of the revenue, for the first 9 months of 2021;
  • Revenue for FY 2021 expected to come at the top end of the €25-27m guidance range, in light of current results.

“In the third quarter, MotorK continued to deliver solid top-line growth driven by the strong performance of our cloud-based SaaS platform that offers a comprehensive suite of products to support the full vehicle lifecycle and the entire customer journey,” commented Marco Marlia, CEO of MotorK. “Our business continues to progress at a fast pace, and we are very satisfied with the performance we delivered this quarter. Looking ahead, we will continue to focus on our growth strategy focused on innovation to further strengthen our value proposition and SaaS offering expansion, as evidenced by our healthy level of R&D investment which was up significantly compared to the prior year. We will also continue to actively identify and leverage organic and inorganic opportunities to win new customers and roll-out additional offerings into new markets and geographies.”

FINANCIAL HIGHLIGHTS

Key Figures

Key figures

Q3 '21

Q3 '20

y.o.y.
change

YTD '21

YTD '20

y.o.y.
change

€'000

Revenue

8,089

4,359

86%

20,870

13,547

54%

Adjusted EBITDA*

1,411

(212)

-

1,749

(1,415)

-

Adjusted EBITDA margin

17.5%

-5%

22%

8%

-10%

19%

*Adjusted EBITDA is defined as EBITDA as adjusted for stock option costs and certain income and costs, which are expected to occur infrequently, and that management considers not reflective of ongoing operational activities. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue.

The Group generated €8.1 million in revenue for the quarter, up 86% compared to the prior year, driven by a strong performance of its SaaS platform, across both the WebSparK and LeadSparK platforms. Revenue this quarter was positively impacted by delivery to a major OEM client in Germany.

Adjusted EBITDA for the quarter was €1.4 million, compared to a €212,000 loss in 2020. The Adjusted EBITDA margin was strong at 17.5%, benefitting from SaaS-driven operating leverage, despite continued investments in R&D and innovation.

Revenue

Revenue by product and service line

The table below shows the Group’s revenue broken down by product and service line for Q3 2021 and Q3 2020, and for the nine-month periods ended September 30, 2021 and September 30, 2020.

 

Revenue by product and service line

Q3 '21

Q3 '20

y.o.y.
change

YTD '21

YTD '20

y.o.y.
change

€'000

SaaS platform revenue

5,738

2,364

143%

12,294

7,091

73%

Digital Marketing revenue

1,799

1,591

13%

5,840

5,060

15%

Other revenue

552

404

37%

2,736

1,396

96%

Total

8,089

4,359

86%

20,870

13,547

54%

With respect to the product and service lines of the Group’s business, the Group’s revenue is derived primarily from its SaaS platform. Revenue generated from the SaaS platform amounted to €5.7 million in the third quarter of 2021, an increase of about €3.3 million or 143% compared to the prior year period, and €12.3 million for the nine-month period ended September 30, 2021, an increase of about €5.2 million, or 73%, compared to the nine-month period ended September 30, 2020.

Research & Development Costs and Investments

Set forth below are the breakdown of the Group’s total R&D spend in absolute terms and as a percentage of the Group’s total revenue for Q3 2021 and Q3 2020, and for the nine-month periods ended September 30, 2021 and September 30, 2020.

R&D spend

Q3 ‘21

Q3 ‘20

y.o.y.
change

YTD ‘21

YTD ‘20

y.o.y.
change

€’000 (except percentages)

Total R&D spend

2,026

1,320

54%

5,351

3,688

45%

- of which capitalised

(800)

(689)

16%

(2,210)

(1,996)

11%

- of which expensed in the income statement

1,226

631

94%

3,141

1,692

86%

Total R&D spend as a percentage of Group total Revenue

25%

30%

-5%

26%

27%

-2%

 

As part of its growth strategy, MotorK has continued to invest in R&D to develop innovative solutions for its customers and expand the capabilities of its SaaS platform. R&D spend reached €2 million in Q3 2021 and €5.4 million for the first 9 months of 2021, up 54% and 45% respectively compared to the same periods in 2020.

OUTLOOK

MotorK expects FY 2021 revenue to come at the top end of the €25-27 million guidance range, in light of current results.

Conference Call Information

Marco Marlia (CEO) and Andrea Servo (CFO) will host a conference call for analysts and investors at 5:00 pm CET to discuss the 2021 third quarter results. A live webcast of the conference call and related earnings materials can be accessed on MotorK’s Investor Relations website (investors.motork.io/). A replay of the webcast will be available through the same link on the website following the conference call.

About MotorK Plc

MotorK (AMS: MTRK) is a leading software as a service (“SaaS”) provider for the automotive retail industry in the EMEA region, with over 300 employees and eight offices in seven countries (Italy, Spain, France, Germany, Portugal, the UK and Israel). MotorK empowers car manufacturers and dealers to improve their customer experience through a broad suite of fully integrated digital products and services. MotorK provides its customers with an innovative combination of digital solutions, SaaS cloud products and the largest R&D department in the automotive digital sales and marketing industry in Europe. MotorK was founded in Italy in 2010 and has been recognised by multiple organisations as one of the fastest growing tech companies in Europe – including Euronext TechShare, Tech Tour 50, Technology Fast 500 EMEA and the FT 1000. For more information, please visit: www.motork.io .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release

Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye